Ninety percent of relapse/refractory B-cell acute lymphatic leukemia (R/R B-ALL) patients can achieve complete remission (CR) after CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy. However, around 50% of them relapse in 1 year.
from 83% to 93%. [5] [6] [7] In contrast, children's response rate was lower than that of adults, expanding from 68% to 90%. 1, 8, 9 Although adults with B-ALL display 10% higher relapse rates compare with pediatric patients and experience long-term event-free survival of less than 50%, it is reported that approximately 25% of pediatric patients have a relapse with CD19 negative or CD19 low and resulted in a considerable number of all childhood cancer deaths. 10, 11 Thus, developing efficient and molecular-targeted approaches to prolong the life-span of B-ALL children has become a vital priority in recent years. CAR-T cells targeting CD19 has successfully shown tremendous potential for Bcell lineage malignancies. 2, 4, 5, 12 Here, we report the safety, efficacy, and correlative studies of CD19 CAR-T cells therapy in 10 pediatric patients in China.
| RESULTS

| Design of CD19 CAR-T cells and patient enrollment
The sequence of CD19 chimeric antigen receptor is composed by CD19 scFv, CD28-hing, 4-1BB costimulatory region, and CD3ζ activation domains ( Figure 1A) . T cells were activated by CD3/CD28 F I G U R E 1 The structure feature of CAR construct (A) including VH, heavy chain variable domain; VL, light chain variable domain, hinge, transmembrane domain, 4-1BB and CD3 ζ. (B) The screen, enrollment criteria, and the treatment microbead 2 days before CD19-CAR lentivirus infection. After transduction, the T cells were expanded for another 10 days before formulation and infusion. The detail of manufacturing of Senl-B19 was outlined in Figure S1.
| Demographics and baseline characteristics
Patients with relapsed or refractory B-ALL in Hebei Second Provincial People Hospital were recruited in the phase I/II clinical trial of CD19 CAR-T cell treatment (NCT02963038). The enrollment procedure is outlined in Figure 1B . Patients' characteristics are summarized in Table 1 . The median age was 6.5 (range 3-13 y); none of them has prior hematopoietic stem cell transplant. All patients have experienced at least three courses of chemotherapy prior CAR-T infusion (median 4, range 3-10 times). Mean bone marrow (BM) blast was 40.8% (range 0% to 86.2%) at the first day (day −5) of standard preconditioning regiment (fludarabine 25 mg/m 2 ; cyclophosphamide 900 mg/m 2 ). All patients were carefully observed in the hospital for the first month to monitor the adverse effect and efficacy. Complete blood counts and cytokine concentration were examined at different time course, including day −1 to 0, day 1, day 4 or 5, day 7, day 10 or 11, day 14, day 21, and day 28. Afterwards, levels of CAR-T cells and residual leukemia cells in BM were analyzed monthly.
| Safety and efficacy
The median percentage of BM blasts (prior treatment) was 59.2% (7.31%-86.2%), excluding one who only with brain infiltration of leukemia cells (0% BM blasts). Patients were infused with various doses of CD19 CAR-T cells as shown in Table 2 . The average dose of treatment was 0.71 × 10 6 cells/kg (range 0.3-1.58 × 10 6 cells/kg), and the average transfection rate was 32.0% ± 24.7%. Most patients received one infusion, except patient 21 infused twice. Cytokine release syndrome (CRS) is the major risk for patients receiving CAR-T cell therapy especially in hematologic malignancy. 13 In this report, six patients encountered grade 1/2 CRS, three patients with grade 3 CRS, and one with grade 4 ( Table 2 ). In addition, central nervous system (CNS) neurotoxicity also occurred in three patients (pts 4, 34, and 68). Toxicities were managed by supportive care ± tocilizumab and/or dexamethasone depending on physicians' instruction. Thirteen cytokines were examined, and six of them were with significantly elevated concentration along with CAR-T cell expansion. The dynamics of cytokine release (TNF-α, INF-γ, and IL-6) were summarized in Figure 2A . The peak of CAR-T cell expansion was around day 7 to day 10 and rapidly decreased within 5 to 10 days ( Figure 2B ). Some patients revealed different adverse effects, which were summarized in Table S1 . Among the 10 patients, eight of them reached minimal residual disease (MRD) negative after first month ( Table 2) , except patient 34 and patient 21. Patient 34 received 1 × 10 6 CAR-T cells/kg, but he was dead because of rapid disease progression within 5 days. Patient 21 infused CAR-T cells twice, but the blast was not controllable, diseased 2 months after first infusion. To date, the status of patients was summarized in Figure 2C .
The median overall survival months and event-free survival months for eight CR patients were 10.3 and 4 months, respectively ( Figure S2A The composition of infused CAR-T cells was further analyzed (Table S2 ). The average of CD3+, CD4+, and CD8+ T cells was 97.7%, 32.4%, and 66.8%, respectively ( Figure 2D ). The expression of PD1 was around 0.24% to 2% (not available for pts 3, 9, and 57), which suggested the activity of infused T cells. Further analysis of the absolute number of CAR-T cells and CD4/CD8 ratio ( Figure 2E ,F) revealed that the T cell population of most patients were CD8 dominant.
| Overall efficacy and CRS response
Three patients (pts) with more than 70% blast in BM receiving 0. CRS is suggested to be correlated with the blast amount. However, the dosages of infusion were sometimes adjusted to reduce the chance of severe CRS; thus, we did not observe a strong correlation between BM blast and CRS degree ( Figure S3 ). The peak concentration of IFN-γ and IL-6, but not IL-8 or IL-18, was slightly correlated with the degree of CRS ( Figure S4 ). In addition, we found that the Figure S6 ). In short, IFN-γ and IL-6 concentrations were correlated with the severity of CRS, but there was no clue to know who would develop strong cytokine release except regularly monitored.
| Relapse and long-term survival
In this report, four patients were relapsed around 3 to 4 months after infusion. According to their last results of flow cytometry analysis and qPCR quantitation before relapse, the detection of CAR DNA suggested the persistence of CD19 CAR-T cells against CD19+ leukemia. The blast phenotypes of patients 4 and 44 were CD19-/CD22-;
for patient 19, it was CD19-/CD22+; and for patient 26, it was a myeloid lineage relapse.
On the other hand, we analyze potential factors that may correlate to long-term survival from many aspects. We found two patients with long-term survival were happened to be high CD4 ratio ( Figure 2E gene 14 resulted in a dominant clone expansion of the specific mutated CAR-T cell. On the basis of that, we were sequencing the samples of the first patient for T cell population, to understand the mechanism of long-term persistency.
| DISCUSSION
In this study, despite the high rate of MRD-negative CR/CRi (8/10, 80%) demonstrates that infusion of our CD19 CAR-T product is an effective salvage therapy for pediatric and young adults with were CD19 loss that suggests a strong correlation between the incidence of CD19-negative relapse and longer BCA duration. However, there were still 25% relapsed patients (2/8) who lost BCA in 2 months after CAR-T therapy were CD19 negative. Therefore, other tumor escape mechanisms besides sustained functional persistence of CAR-T cells cannot be excluded. The absence of subsequent allo-SCT may also increase the chances of antigen-loss relapse. In our study, no CR patients received further therapy including allo-HCT that might potentially lead to a high rate of CD19-negative relapse.
To be noted, pt 3 is still under CR with BCA for more than 2 years.
The persistence of CAR-T cells and the retainment of antileukemia functionality were detected as long as 2 years after treatment (Figure 4) . Despite the long duration of BCA, we have not observed obvious serious adverse effects correlated with BCA with a closely following up during the past 2 years. During the time, and long-term persistence of functional CAR-T cells were detected as long as 2 years after treatment, which is consistent with previous speculate. She only encountered one pneumonia and stayed in the hospital for 10 days.
There were no other complications within all these days. On contrary, the other three sustained remission patients lost BCA at 2 to 4 months after CAR-T infusion ( Table 2 ). Our data have not shown a clear correlation of sustained remission status with the duration of BCA.
Immunologists have been looking for methods to prolong the persistence of CAR-T cells, including CAR-T derived from central memory T cells, 16 confined subset of CD4+ and CD8+ T cells, 17 or CD4+ T cells alone. 18 Lately, Wang et al highlight the pivotal role of CD4+ T cells in xenograft models 19 and consolidated their scheme with the results from their clinical trials. Interestingly, two patients with high CD4/CD8 CAR-T ratio, in this study, were continuously in CR and BCA, which was in consent with Wang's observation. 19 This observation suggests that high CD4 ratio may benefit long-term survival. And then the CAR-T cells were transferred to a culture bag on the 6th day and expanded in it for another 10 to 12 days before infusion. 
| Clinical study
| Immunophenotyping
Tumor cells and T cells were phenotyping with CD3-APC (OKT3, 
| Cytokine measurement
The 
| Statistics
We used descriptive statistics (means and standard deviations or median and ranges) to summarize the data. The relationships between overall survival time and the ratio of CD4+CAR-T/CD8+CAR-T as well as cytokines (IL-8, IL-18, and MCP-1) and the blast percentage in BM, respectively, were analyzed by linear regression models using the generalized estimating equations method. Pearson correlation was used to test the statistical relationship between two variables. Data were plotted using OriginPro7.5. The survival curve and progression-free survival (PFS) were determined by the Kaplan-Meier method. P value < .05 was considered to be statistically significant.
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